Black Mould, Falsified Records, and Import Alert 66-40: What FDA Inspection Reports Reveal About Chinese GLP-1 API Suppliers

Key takeaways

• Inspection reports obtained under the Freedom of Information Act document black mould on equipment, "gross contamination" on floors, and "significant insect activity" at Chengdu Shengnuo Biopharm Co. during an August 2026 visit.
• During the same inspection, quality-control staff were observed removing laboratory documents from the facility and concealing them in lockers, whilst personnel poured out product samples in what inspectors described as "a seemingly coordinated effort."
• A separate September 2026 inspection at Nanjing Chengong Pharmaceutical Co. found staff affixing their own company's approval seal to active pharmaceutical ingredients sourced from third-party manufacturers, without reviewing the source manufacturers' testing or safety data.
• Both firms supply semaglutide and tirzepatide APIs used in compounded versions of GLP-1 medications. Neither facility's compounded output carries FDA approval or review for safety and effectiveness.
• The FDA placed both companies on Import Alert 66-40 — the agency's Detention Without Physical Examination mechanism for facilities that have failed to meet current Good Manufacturing Practice — meaning border officers may block shipments without individual testing.
• Chengdu Shengnuo, a unit of listed Chinese group Sheng Nuo Biotec, has stated it is working to address the findings; its stock fell approximately 18 per cent on the announcement of the import alert in September 2026.
• The disclosures arrive as the FDA and HHS simultaneously advance an "interim access policy" to expand compounding pharmacy access to certain unapproved peptides, a juxtaposition that raises substantive questions for procurement professionals about how API sourcing standards will be enforced in a deregulatory environment.

What the inspection reports document

On 15 October 2026, Bloomberg published details from FDA inspection reports obtained through a FOIA request, revealing what the agency described as egregious conditions at two Chinese facilities supplying active pharmaceutical ingredients for compounded GLP-1 medications widely used in the United States.

Inspection reports describe significant failures at two Chinese facilities supplying active ingredients for compounded GLP-1 drugs. At Chengdu Shengnuo, inspectors noted black mould on equipment, "gross contamination" on floors, and "significant insect activity" in the ceilings.

The conduct of personnel during the inspection compounded concerns about the facility's quality governance. As inspectors arrived in August, quality staff were seen hustling laboratory papers into a nearby room and stuffing them into lockers, whilst personnel were observed dumping product samples into sinks "in a seemingly coordinated effort." Inspectors were unable to recover all of the papers.

According to the FOIA-obtained reports, Chengdu Shengnuo Biopharm Co. underwent on-site inspections by FDA inspectors from 20 August 2026 to 22 August 2026, and on 24 and 27 August 2026. On 27 August, the FDA issued a Form FDA 483 Observations notice to the company, identifying eight observations primarily related to a specific product group and a particular production and packaging process.

The conditions at the second facility were qualitatively different but equally significant from a supply-chain integrity perspective. A September 2026 visit to Nanjing Chengong Pharmaceutical found workers buying active ingredients produced by other manufacturers and applying Nanjing Chengong's own approval seal to those materials, whilst staff failed to examine the source manufacturers' testing data to verify the safety of the products.

Import Alert 66-40 and its practical effect

Both firms were placed on the FDA import-alert list, allowing their products to be stopped from entering the US. The FDA added both companies to Import Alert 66-40, meaning their shipments can be blocked at the border.

Import Alert 66-40 operates through a Detention Without Physical Examination mechanism: customs officers can refuse entry to any shipment from a listed firm without first testing individual consignments. The burden of proof shifts to the manufacturer to demonstrate compliance before shipments are released.

Chengdu Shengnuo Biopharm was placed on Import Alert 66-40 effective 19 September 2026. On 17 September 2026, the company had submitted its initial response to the FDA 483 observations, along with corresponding corrective actions, to the Office of Manufacturing Quality within CDER. However, apart from the FDA 483, the company states it has not yet received an official action indication or a warning letter.

The import alert stems from eight observations documented in the Form FDA 483, covering critical quality attribute identification, contamination control capabilities, and quality system governance. In the first half of 2026, the company's US sales reached approximately 167 million yuan (around $24.9 million), accounting for 32.83 per cent of total revenue.

Following the news, Shengnuo's stock fell approximately 18.61 per cent. The company stated it is actively pursuing corrective actions and communicating with the FDA to resolve the alert.

Chengdu Shengnuo Biopharm Co. is a unit of Chengdu Shengnuo Biotec Co., and stated in a Chinese regulatory filing that it has been "diligently implementing effective measures" to address the problems.

The products in question

The companies produced semaglutide and tirzepatide for compounded versions of Novo Nordisk and Eli Lilly blockbusters that are not FDA-approved or reviewed for safety or effectiveness.

Shengnuo Biotech is an active pharmaceutical ingredient company whose most scrutinised business segment is GLP-1 peptide APIs, including semaglutide API and tirzepatide API; the latter was filed with the FDA in May 2026.

This matters because compounded GLP-1 medications rely entirely on the purity and identity of the bulk API supplied by manufacturers such as these. Unlike finished drug products from branded manufacturers, compounded preparations do not undergo FDA batch release review. A compounding pharmacy's quality assurance is therefore wholly dependent on the standards of its upstream API supplier — and on the validity of the Certificates of Analysis those suppliers provide.

A broader pattern of GMP failures in Chinese GLP-1 API supply

The Shengnuo and Nanjing Chengong findings are not isolated. The FDA's Import Alert 66-40 already lists Chengdu Brilliant Biopharmaceutical Co., which was placed on the alert on 9 July 2025 following separate GMP findings; that firm received a formal warning letter in September 2025.

Notably, agency records list Chengdu Shengnuo's last inspection prior to August 2026 as September 2023, and Nanjing Chengong's as March 2025, raising questions about inspection frequency relative to the pace at which Chinese GLP-1 API production expanded after the US semaglutide shortage declaration in 2022.

The congressional dimension is also significant. A January 2026 letter from the House Select Committee on the Chinese Communist Party to Chinese manufacturer Fujian Genohope noted that a study found that following the FDA's 2022 declaration of a semaglutide and tirzepatide shortage, there was a substantial increase in Chinese companies manufacturing these molecules for import into the US. The same study found that less than a quarter of all Chinese facilities marketing semaglutide bulk had been inspected by the FDA since beginning manufacture of the product, and approximately 60 per cent of such facilities were not registered with the FDA at all prior to the shortage announcements.

The regulatory context: interim access and API standards

The timing of these disclosures is notable. On 15 October 2026 — the same day the Bloomberg report appeared — the Department of Health and Human Services and the FDA submitted an "interim access policy for compounding using certain peptides" for White House review, according to a filing on the Office of Management and Budget's website.

The new policy would essentially assure compounding pharmacies that they would not be targeted for producing certain peptides. That approach, known as enforcement discretion, allows the FDA to selectively choose not to enforce some of its own regulations.

Formally adding the peptides to the FDA's list of drugs that are safe for compounding would require federal rulemaking, a process that could take years and involves multiple rounds of public comment.

For UK research-procurement professionals, this juxtaposition is instructive. An administration signalling reduced enforcement for compounding — while simultaneously blocking shipments from API suppliers found to have engaged in document concealment and source substitution — illustrates the dual-track nature of current US peptide regulation. Enforcement discretion applies at the dispensing end; it does not relax the underlying GMP obligations on API manufacturers.

Procurement implications for UK research laboratories

UK research facilities do not source compounded GLP-1 drugs directly from US pharmacies, but the Chinese API supply chain feeding US compounders overlaps substantially with the bulk peptide trade serving European research and analytical markets. Several practical considerations follow from this week's findings:

Certificate of Analysis verification. The Nanjing Chengong findings demonstrate that a supplier's own CoA may reflect third-party material without disclosure. UK procurement policies should require that CoAs be cross-referenced against the drug master file (DMF) registration of the specific manufacturing site — not simply the commercial entity placing the seal.

Import alert monitoring. The FDA's Import Alert 66-40 database is publicly searchable and updated in near-real time. Procurement teams sourcing semaglutide, tirzepatide, or related GLP-1 peptide APIs from Chinese manufacturers should cross-check supplier names against this list at each new order.

Audit trail for source manufacturers. Where a supplier is purchasing API from a third party and repackaging under its own label, the source manufacturer's identity and inspection history must be independently verifiable. This mirrors the MHRA's expectation under the UK's retained EU legislation on falsified medicines: the supply chain must be traceable to the point of synthesis.

Batch-level analytical testing. Given the pattern of documentation irregularities now disclosed across multiple Chinese GLP-1 API suppliers, reliance on supplier-provided testing data alone is insufficient. Independent identity and purity testing — using validated HPLC or LC-MS methods — should be conducted on each incoming batch before use in any downstream application.

Sources: Bloomberg | Briefs.co | Quartz | Jingletree | Futunn / Shengnuo regulatory filing | VCBeat Health | BigGo Finance | FDA Import Alert 66-40 | FDA Warning Letter — Chengdu Brilliant | Reuters / Yahoo News | House Select Committee on the CCP letter